期刊
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH
卷 8, 期 3, 页码 165-178出版社
FUTURE MEDICINE LTD
DOI: 10.2217/cer-2018-0134
关键词
apixaban; atrial fibrillation; clinical practice; dabigatran; edoxaban; rivaroxaban
Aim: To analyze the effectiveness and safety of direct oral anticoagulants (DOACs) in atrial fibrillation (AF) patients attended in clinical practice. Methods: Observational and prospective study of AF patients that started treatment with DOACs. Results: 1443 patients (age 77.2 +/- 9.7 years, CHA(2)DS(2)-VASc=4.1 +/- 1.5) were included. 46.0% were taking rivaroxaban, 24.4% dabigatran, 22.5% apixaban and 7.1% edoxaban. Patients taking dabigatran were younger, had lower CHA(2)DS(2)-VASc and lesser renal insufficiency. Patients taking apixaban had higher CHA(2)DS(2)-VASc and more renal insufficiency. Rates of stroke/major bleeding/intracranial bleeding were 0.7/1.3/0.2 events/100 patient-years, respectively. Conclusion: This was the first prospective study that analyzed the use of all DOACs in AF patients in Spain, showing a good profile in terms of safety and effectiveness in accordance with pivotal studies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据